Growth capital fundraising for DCN Diagnostics, Inc.
DCN Diagnostics, Inc. (“DCN Dx”) is a leading specialist developer of lateral flow technology. Based in Carlsbad, CA, it offers a full suite of consulting, design, development and manufacturing solutions to clients seeking to develop lateral flow assays, mainly for diagnostics applications.
DCN Dx’s CDMO services cover all stages of the creation of a new lateral flow assay, including: (i) education courses, (ii) assay and test strip conceptualisation and feasibility analysis, (iii) product regulatory path guidance, (iv) prototyping and development, (v) assay optimisation and verification, and (vi) gap and full manufacturing.
Pegasus Capital was appointed by the board of DCN Dx to source growth capital to fund the continued expansion of the business. This process cumulated in Martis Capital, a San Francisco, CA, healthcare-focused private equity firm taking a major stake in the business.
“Pegasus were an invaluable resource throughout our process. They displayed deep domain expertise and exceptional tenacity, organisation and skill in executing a deal that represents a great outcome for all involved.”
Brendan O’Farrell
CEO and President, DCN Diagnostics
Year: 2020
Sector: Healthcare
Terms: Not disclosed
Further Transactions
